Özet:

Prostate-specific antigen (PSA) is the most commonly used marker in the screening of prostate cancer which is the most common solid tumor in men. Although PSA is specific for prostate, its specificity for prostate cancer is low and its false negative rate is high. With PSA-based screening, disease-specific mortality has declined in recent years, but this has led some patients to receive overdiagnosis, unnecessary biopsies and unnecessary treatment. In recent years, new biomarkers have been developed that can provide specific and early diagnosis of prostate cancer to resolve these problems. In this review, the biomarkers and imaging methods used for the diagnosis and screening of prostate cancer will be evaluated in the light of current literature.

Anahtar Kelimeler: